General Newsroom Hero 1920x480 (4:1)
Our Work

Latham & Watkins Advises ALASTIN Skincare® on Acquisition by Galderma

November 29, 2021
A corporate team represents the physician-dispensed skincare brand in the transaction

Galderma, the world’s largest independent dermatology company, announced that it has signed a definitive agreement to acquire ALASTIN Skincare®, Inc. (ALASTIN), a specialty aesthetics company dedicated to developing innovative and clinically-tested physician-dispensed skincare products. The acquisition is subject to customary closing conditions and necessary regulatory approvals. 

Latham & Watkins LLP represents ALASTIN in the acquisition with a corporate team led by Orange County partner Daniel Rees and San Diego partner Cheston Larson with associates Madison Mapes, Claire Hutar, Mekbeb Hagos, and Erik Jensen. Advice was also provided on compensation and benefits matters by San Diego partner Holly Bauer with associate Mario Moreno; on tax matters by Century City partner Samuel Weiner with associate Seung Yang; on intellectual property and data privacy matters by San Diego counsel Darryl Steensma and Bay Area counsel Robert Blamires with associates Kathryn Parsons-Reponte and Michael Sweeney; on antitrust matters by Washington, D.C. partner Jason Cruise and Washington, D.C. counsel Patrick English; on FDA matters by Washington, D.C. partner Elizabeth Richards with associate Kathryn Culver; on insurance matters by Los Angeles partner Drew Levin with associate Harrison White; and on CFIUS matters by Washington, D.C. partner Jim Barker.